EICHORPublic-registry trials using ST-0529 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
ST-0529 appears in 1 registered trial Eichor's radar has found, sponsored by Sublimity Therapeutics Holdco Limited, the most recent registered as Phase 2, with a planned enrollment of 235. Registered timeline: 2019–2021. The registry holds 1,879 registered studies for Colitis, Ulcerative.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis | Sublimity Therapeutics Holdco Limited | Colitis, Ulcerative | PHASE2 | 89 |
| Status | Terminated · planned start 2019-01 |
| Primary completion | 2021-04 |
| Enrollment target | 235 participants |
| Design | Randomized · Parallel · Phase 2 · 4 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 89 listed in Belarus, Bulgaria, Canada, France |
All fields verbatim from the ClinicalTrials.gov record for NCT03844932.
| First registered study | February 2019 — NCT03844932 (Sublimity Therapeutics Holdco Limited) |
| Registered studies matching this name | 1 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 1,879 registered studies for Colitis, Ulcerative. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Colitis, Ulcerative studies · Weekly briefs
